XML 42 R32.htm IDEA: XBRL DOCUMENT v3.23.2
Revenue- Incyte Corporation (Details)
$ in Thousands
 1 Months Ended 3 Months Ended 6 Months Ended 7 Months Ended 9 Months Ended 24 Months Ended 63 Months Ended
Mar. 31, 2023
USD ($)
Jun. 30, 2023
USD ($)
Jun. 30, 2022
USD ($)
Jun. 30, 2023
USD ($)
Jun. 30, 2022
USD ($)
Jul. 31, 2022
USD ($)
Sep. 30, 2021
USD ($)
Sep. 30, 2018
USD ($)
Dec. 31, 2018
USD ($)
performanceObligation
Mar. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Jan. 31, 2022
Collaboration And Other Agreements [Line Items]                        
Revenues   $ 13,136 $ 26,007 $ 37,632 $ 37,108              
Deferred revenue, current   9,671   9,671             $ 9,988  
Deferred revenue, net of current portion   58,538   58,538             $ 59,480  
Incyte Corporation | Incyte MGA012 Agreement                        
Collaboration And Other Agreements [Line Items]                        
Non-refundable upfront payment               $ 150,000        
Potential commercial milestone payments under agreement                 $ 330,000      
Potential development and regulatory milestone payments under agreement                 435,000      
Development and regulatory milestones recognized $ 15,000                 $ 115,000    
Collaborative agreement transaction price                 154,000      
Variable consideration recognized                 $ 4,000      
Number of performance obligations | performanceObligation                 2      
I-Mab | I-Mab Biopharma Collaboration and License Agreement                        
Collaboration And Other Agreements [Line Items]                        
Non-refundable upfront payment             $ 15,000          
Revenues   0 600 0 700              
Development and regulatory milestones recognized       5,000                
Minimum | Incyte Corporation | Incyte MGA012 Agreement                        
Collaboration And Other Agreements [Line Items]                        
Potential proceeds from royalties (percent)               15.00%        
Maximum | Incyte Corporation | Incyte MGA012 Agreement                        
Collaboration And Other Agreements [Line Items]                        
Potential proceeds from royalties (percent)               24.00%        
Revenues From License Agreements | Incyte Corporation | Incyte MGA012 Agreement                        
Collaboration And Other Agreements [Line Items]                        
Revenues     0 15,000 0     $ 150,000        
Revenues From License Agreements | Incyte Corporation | Incyte MGA012 Clinical Services                        
Collaboration And Other Agreements [Line Items]                        
Revenues   100 200 1,400 500              
RevenuesFromCMOAgreementsMember | Incyte Corporation                        
Collaboration And Other Agreements [Line Items]                        
Non-refundable upfront payment           $ 10,000            
Annual Fixed Payments   14,400   14,400                
Revenues   1,600 $ 4,000 5,200 $ 4,000              
Deferred revenue   9,000   9,000                
Deferred revenue, current   7,500   7,500                
Deferred revenue, net of current portion   1,500   1,500                
RevenuesFromCMOAmendmentAgreement | Incyte Corporation                        
Collaboration And Other Agreements [Line Items]                        
Annual Fixed Payments   19,500   19,500                
Additional Payments   $ 5,100   $ 5,100                
Manufacturing Services | Incyte Corporation                        
Collaboration And Other Agreements [Line Items]                        
Extension term           1 year            
Manufacturing Services | Incyte Corporation | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-02-01                        
Collaboration And Other Agreements [Line Items]                        
Revenue, remaining performance obligation, expected timing of satisfaction                       3 years